AUR-AE6Y-TTP1-A-1-0-R-A741-41
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.460
- G2M_CHECKPOINT+0.450
- ALLOGRAFT_REJECTION+0.350
- INTERFERON_GAMMA_RESPONSE+0.340
- INTERFERON_ALPHA_RESPONSE+0.290
- IL6_JAK_STAT3_SIGNALING+0.270
- MITOTIC_SPINDLE+0.270
- INFLAMMATORY_RESPONSE+0.210
- MYC_TARGETS_V2+0.200
- SPERMATOGENESIS+0.180
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- COAGULATION-0.390
- BILE_ACID_METABOLISM-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- ESTROGEN_RESPONSE_LATE-0.350
- FATTY_ACID_METABOLISM-0.350
- MYOGENESIS-0.340
- ADIPOGENESIS-0.330
- ESTROGEN_RESPONSE_EARLY-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AFEA-TTM6-A-1-0-R-A741-41 | — | D | 0.908 |
| 2 | TCGA-D8-A147-01A-11R-A115-07 | — | E | 0.890 |
| 3 | SRR1313149 | — | D | 0.845 |
| 4 | SRR1313128 | — | D | 0.843 |
| 5 | 924ccfdb-f369-4b69-a034-bfbaf0878842 | — | — | 0.839 |
| 6 | TCGA-96-A4JL-01A-11R-A24Z-07 | — | cohortSQ1 | 0.828 |
| 7 | TCGA-E2-A1AZ-01A-11R-A12P-07 | — | D | 0.813 |
| 8 | TCGA-FD-A43P-01A-31R-A23W-07 | — | — | 0.811 |
| 9 | SRR10900596 | — | — | 0.807 |
| 10 | SRR8613719 | — | D | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.030 | Idelalisib | — uncovered |